Intercept Pharmaceuticals, Inc. (ICPT)

37.27
NASDAQ
Prev Close 37.39
Day Low/High 36.74 / 38.31
52 Wk Low/High 27.02 / 125.00
Exchange NASDAQ
Shares Outstanding 32.99B
Market Cap 1.23B
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Intercept Pharmaceuticals Plans Changes to Its Fatty Liver Disease Study

Intercept Pharmaceuticals Plans Changes to Its Fatty Liver Disease Study

Intercept says it received approval from the FDA.

Morning Movers and Shakers

We're in the middle of earnings season, and that means big moves for individual names. All the following companies are on the move prior to today's opening bell: Nvidia is the big story today after reporting strong earnings after the close. The stoc...

Trader's Daily Notebook: For a Decline, It Sure Was Smooth

Trader's Daily Notebook: For a Decline, It Sure Was Smooth

But we could see more volatility in the market.

How To Bet Against Tesla Using Convertible Bonds

How To Bet Against Tesla Using Convertible Bonds

Investors seeking to bet against Tesla's common stock may want to give its convertible bonds a spin.

Biotech Is Ripe for M&A: Analysts

After an asset price drop, large pharmaceutical companies are looking for strategic purchases.

Biotechs and Oil Cool As Broad Market Flattens

The broad market remains pretty flat this afternoon after giving up its solid early gains. Biotech is also taking a rest from its huge rally since March 30, giving back a bit more than 1% so far today. However, there's some interesting action on Int...

This Isn't What This Market Needs

A flood of supply in a nervous market isn't a good idea.

Intercept rated new Outperform at JMP

Intercept upgraded at Leerink

A Market Made of Teflon

A Market Made of Teflon

Not even Vladimir Putin can put a scare into this action.

Enjoy the Pause

Enjoy the Pause

Healthy consolidation has become a lost art in this market.

A Good Sign for Active Traders

A Good Sign for Active Traders

Three days of gains without a lot of anxious chasing.

Trading Just like the Old Days

Trading Just like the Old Days

Before the central bankers were the only thing that mattered.

Things Are Different Now

Things Are Different Now

This market is for trading, not for dogmatic bullishness.

Five Dumbest Things on Wall Street, January 17

Five Dumbest Things on Wall Street, January 17

TheStreet's Gregg Greenberg has the list of the Wall Street shenanigans you may have missed this week.

Making a Play on Goldman Sachs

Making a Play on Goldman Sachs

 I will take an unbalanced butterfly approach with a cost very close to zero.

Watch Out for Mr. Downside

Watch Out for Mr. Downside

I see no choice but to play defense and prepare for more bleeding.

New Insight Into Retail Investors

New Insight Into Retail Investors

I've been pleasantly surprised by my conversations with folks at my recent book signings.

Short-Term Mood Is Upbeat

Short-Term Mood Is Upbeat

But you won't see it if you measure the market based on the indices.

IPO Wave Not Receding

Quietly, the IPO market is back. The number of deals peaked at 214 in 2007, plunging to only 31 in 2008, but climbed back to 128 in 2012. Those deals raised $42.6 billion, a touch below the $49 billion raised in 2007. Forty-four were private-equity-...

Go Slow With Pharma IPOs: KYTHERA, Intercept

Go Slow With Pharma IPOs: KYTHERA, Intercept

Francis Gaskins, president of IPO Desktop, says he's going to sit on the sidelines with KYTHERA and Intercept.